CEMIP and prostate carcinoma: In recent years, well-documented studies have demonstrated that KIAA1199 plays a role in promoting malignant progression and predicts poor prognosis of cancer patients, including gastric cancer [14–16], pancreatic cancer [17], colorectal cancer [18, 19], prostate cancer [20, 21] and so on.